Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 68Active not recruiting 17Terminated 14Not yet recruiting 6Withdrawn 4Unknown 3Recruiting 3Approved for marketing 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1CNS 1

Conditions

Primary Myelofibrosis 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × AZD 6244 × Clear all
NCT06188741 2026-03-12

NF114

University of Alabama at Birmingham

Phase 2 Recruiting
200 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT03326310 2025-12-29

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

University of Chicago

Phase 1 Recruiting
18 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡